Cogent Biosciences Statistics
Total Valuation
COGT has a market cap or net worth of $528.65 million. The enterprise value is $259.04 million.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, before market open.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
COGT has 113.93 million shares outstanding. The number of shares has increased by 30.36% in one year.
| Current Share Class | 113.86M |
| Shares Outstanding | 113.93M |
| Shares Change (YoY) | +30.36% |
| Shares Change (QoQ) | +1.17% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 76.95% |
| Float | 78.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.52 |
| P/TBV Ratio | 3.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.32, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.32 |
| Quick Ratio | 5.15 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -99.54% and return on invested capital (ROIC) is -62.67%.
| Return on Equity (ROE) | -99.54% |
| Return on Assets (ROA) | -53.78% |
| Return on Invested Capital (ROIC) | -62.67% |
| Return on Capital Employed (ROCE) | -101.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.25M |
| Employee Count | 205 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.36% in the last 52 weeks. The beta is 0.20, so COGT's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -29.36% |
| 50-Day Moving Average | 6.33 |
| 200-Day Moving Average | 8.82 |
| Relative Strength Index (RSI) | 40.18 |
| Average Volume (20 Days) | 1,618,137 |
Short Selling Information
The latest short interest is 14.33 million, so 12.58% of the outstanding shares have been sold short.
| Short Interest | 14.33M |
| Short Previous Month | 13.00M |
| Short % of Shares Out | 12.58% |
| Short % of Float | 18.32% |
| Short Ratio (days to cover) | 9.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -275.94M |
| Pretax Income | -227.05M |
| Net Income | -255.86M |
| EBITDA | -273.49M |
| EBIT | -275.94M |
| Earnings Per Share (EPS) | -$2.46 |
Full Income StatementBalance Sheet
The company has $287.08 million in cash and $17.47 million in debt, giving a net cash position of $269.61 million or $2.37 per share.
| Cash & Cash Equivalents | 287.08M |
| Total Debt | 17.47M |
| Net Cash | 269.61M |
| Net Cash Per Share | $2.37 |
| Equity (Book Value) | 256.29M |
| Book Value Per Share | 1.32 |
| Working Capital | 240.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$207.79 million and capital expenditures -$573,000, giving a free cash flow of -$208.36 million.
| Operating Cash Flow | -207.79M |
| Capital Expenditures | -573,000 |
| Free Cash Flow | -208.36M |
| FCF Per Share | -$1.83 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |